Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Fluciclovine F18 · Axumin, FACBC

Radiopharmaceutical · Acts on LAT-1 (SLC7A5) · developed by Blue Earth Diagnostics

Approved FDA

1 Registered trials

What is Fluciclovine F18?

Fluciclovine F18 (Axumin) is a synthetic amino acid radiotracer labeled with fluorine F18 for PET imaging. It is transported into cells via amino acid transporters LAT-1 and ASCT2, which are upregulated in prostate cancer cells, allowing preferential accumulation in tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Axumin, FACBC, GE-148, anti-3-[18F]FACBC, [18F]FACBC
Drug type: Radiopharmaceutical
Targets: LAT-1 (SLC7A5) (biomarker), ASCT2 (SLC1A5) (biomarker)
Mechanism: Acts on LAT-1 (SLC7A5)
Pathways: amino acid transport
Therapy area: Oncology
Developer: Blue Earth Diagnostics
In trials of: TLX
FDA status: Approved as Axumin, NDA208054 · FDA label
UNII: 38R1Q0L1ZE

✅ FDA-approved uses

Prostate cancer recurrence

From the indications section of the FDA label (version of Mar 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03762759	Phase 2	Prostate Adenocarcinoma	Active not recruiting	TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Adenocarcinoma

Other drugs acting on SLC7A5

Iodine I 131 IPA Phase 1 QBS10072S Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z